Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial.

Jordan SE, González-Martin A, Morlock R, Hubig L, Yonemori K, Eberst L, Zikan M, Kim HS, Banerjee S, Damian F, Salutari V, Henry S, Raimondo M, Kolinsky M, Woelber L, Tromp J, Hietanen S, Nishio S, Lee JY, Manso L, Cruz F, Barraclough L, Oaknin A, Van Nieuwenhuysen E, Randall L, Lo SH, Mutebi A, Abrahami D, Leary A, Vergote I

Open source

DOI: 10.1016/j.ijgc.2026.104947
Published: 2026 Aug 11
Container: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ijgc.2026.104947,
  title = {Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial.},
  author = {Jordan SE and González-Martin A and Morlock R and Hubig L and Yonemori K and Eberst L and Zikan M and Kim HS and Banerjee S and Damian F and Salutari V and Henry S and Raimondo M and Kolinsky M and Woelber L and Tromp J and Hietanen S and Nishio S and Lee JY and Manso L and Cruz F and Barraclough L and Oaknin A and Van Nieuwenhuysen E and Randall L and Lo SH and Mutebi A and Abrahami D and Leary A and Vergote I},
  year = {2026},
  journal = {International journal of gynecological cancer : official journal of the International Gynecological Cancer Society},
  doi = {10.1016/j.ijgc.2026.104947},
  url = {https://doi.org/10.1016/j.ijgc.2026.104947}
}

RIS

TY  - JOUR
TI  - Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial.
AU  - Jordan SE
AU  - González-Martin A
AU  - Morlock R
AU  - Hubig L
AU  - Yonemori K
AU  - Eberst L
AU  - Zikan M
AU  - Kim HS
AU  - Banerjee S
AU  - Damian F
AU  - Salutari V
AU  - Henry S
AU  - Raimondo M
AU  - Kolinsky M
AU  - Woelber L
AU  - Tromp J
AU  - Hietanen S
AU  - Nishio S
AU  - Lee JY
AU  - Manso L
AU  - Cruz F
AU  - Barraclough L
AU  - Oaknin A
AU  - Van Nieuwenhuysen E
AU  - Randall L
AU  - Lo SH
AU  - Mutebi A
AU  - Abrahami D
AU  - Leary A
AU  - Vergote I
PY  - 2026
JO  - International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
DO  - 10.1016/j.ijgc.2026.104947
UR  - https://doi.org/10.1016/j.ijgc.2026.104947
ER  -

APA

SE, J., A, G., R, M., L, H., K, Y., L, E., M, Z., HS, K., S, B., F, D., V, S., S, H., M, R., M, K., L, W., J, T., S, H., S, N., JY, L., L, M., F, C., L, B., A, O., E, V. N., L, R., SH, L., A, M., D, A., A, L., & I, V. (2026). Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial.. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. https://doi.org/10.1016/j.ijgc.2026.104947

Source records

pubmed · retrieved 2026-09-25T11:36:42.686Z